|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predictors of positive <sup>18</sup>F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica.
|
29903537 |
2019 |
|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnostic performance of <sup>18</sup>F-FDG PET-CT for large vessel involvement assessment in patients with suspected giant cell arteritis and negative temporal artery biopsy.
|
30976984 |
2019 |
|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conventional 18F-FDG PET/CT is an accurate and reliable tool to diagnose cranial arteritis in glucocorticoid-naïve GCA patients.
|
30066157 |
2019 |
|
Giant Cell Arteritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inclusion criteria for the qualitative analysis were (1) <sup>18</sup>F-FDG PET used to assess the disease activity, (2) The use of the ACR criteria for the diagnosis of TAK, (3) No case mixed vasculitis (i.e., no giant cell arteritis), and (4) CRP concentration and clinical disease activity available.
|
28856429 |
2018 |
|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 130 consecutive 18F-FDG PET/CT scans performed during the disease course for evaluating disease activity in 15 GCA and 13 TAK patients were retrospectively examined by two nuclear physicians blinded to clinical data.
|
29799393 |
2018 |
|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy.
|
29671039 |
2018 |
|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unusual and Diffuse Hypermetabolism in Routine 18F-FDG PET/CT of the Supra-aortic Vessels in Biopsy-Positive Giant Cell Arteritis.
|
30015661 |
2018 |
|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
[18F]FDG positron emission tomography in patients presenting with suspicion of giant cell arteritis-lessons from a vasculitis clinic.
|
29126277 |
2018 |
|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The radiotracer, <sup>18</sup>F-FDG has proven to be useful in the diagnosis of giant cell arteritis (GCA), a form of LVV.
|
29729443 |
2018 |
|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also discuss the sensitivity of FDG-PET imaging in differentiating polymyalgia rheumatica from other diseases that have similar clinical presentation.
|
30322478 |
2018 |
|
Giant Cell Arteritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 4 separate studies in the current protocol focus on: the association of clinical picture of PMR/GCA with PET findings; the validity of 18F-FDG PET/CT scan for diagnosis of PMR/GCA compared with temporal artery biopsy; the prevalence of newly diagnosed malignancies in patients with PMR/GCA, or PMR-like syndrome, with the focus on diagnostic accuracy of 18F-FDG PET/CT scan compared with conventional workup (ie, chest X-ray/abdominal ultrasound); and the impact of disease process, and also steroid treatment on bone mineral density, body composition, and vasculitis/vascular stiffness in PMR/GCA patients.
|
28658131 |
2017 |
|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aortitis in giant cell arteritis: diagnosis with FDG PET/CT and agreement with CT angiography.
|
28911987 |
2017 |
|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Repetitive <sup>18</sup>F-FDG-PET/CT in patients with large-vessel giant-cell arteritis and controlled disease.
|
28865740 |
2017 |
|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Five out of 15 patients presented with increased <sup>18</sup>F-FDG accumulation in large arteries as a sign of giant cell arteritis.
|
28265227 |
2017 |
|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some patients also present with high <sup>18</sup>F-FDG uptake in main arteries, corresponding to the characteristics of giant cell arteritis.
|
28508663 |
2017 |